elafibranor Iqirvo PBC
Selected indexed studies
- Elafibranor: First Approval. (Drugs, 2024) [PMID:39110316]
- Latest FDA approved drug Elafibranor (Iqirvo): a novel prospect for treatment of primary biliary cholangitis. (Ann Med Surg (Lond), 2025) [PMID:40109633]
- Elafibranor for primary biliary cholangitis: a dual PPAR agonist changing the treatment landscape. (Ann Med Surg (Lond), 2025) [PMID:40851978]
_Worker-drafted node — pending editorial review._
Connections
No connections recorded yet.
Sources
- Elafibranor: First Approval. (2024) pubmed
- Latest FDA approved drug Elafibranor (Iqirvo): a novel prospect for treatment of primary biliary cholangitis. (2025) pubmed
- Elafibranor for primary biliary cholangitis: a dual PPAR agonist changing the treatment landscape. (2025) pubmed
- PMID:40857367 (2025) pubmed
- PMID:42118891 (2026) pubmed